chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A girl of 11 years and 6 months of age received the first dose of the Pfizer-BioNTech  COVID-19 vaccine. 3rd party organization were in charge of intake. Potentially, one volunteer from these organizations misread the date of birth of the patient during patient intake. Because the patient and her mother spoke a different language, they potentially did not know about the age requirement. vaccination administered. Because there was a 12 written on the form above the DOB section and the birth year was correct, he misread the date of birth and assumed the patient was 12. No reaction was observed from the vaccination. The patient was alert and oriented upon leaving after the 15 minute observation period. Patient's mother was unable to be reached by telephone; however, the mother's partner was reached by telephone and reported that patient was in good condition the day after the vaccination.
pt recv vax 16SEP96 & SEP96 pt exp a fever & devel high liver func tests;
4 days after vaccine had visual change, vomiting 3 times, migraine type headache. 5th day felt better but some back pain.
Flu-like symptoms; achiness; severe chills; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 08Apr2021 at 09:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included none. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) for unknown indication from unknown start date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient not had any known allergies to medication, food or any other products. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 18Mar2021 at 09:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested for COVID-19. On 08Apr2021 at 12:00 the patient experienced Flu-like symptoms - achiness, fatigue, severe chills and they lasted approximately 12 hours. The event did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events Flu-like symptoms - achiness, fatigue, severe chills were recovered on 09Apr2021, approximately after the duration of 12 hours.  No follow-up attempts are needed. No further information is expected.
Vertigo and fatigue resulting in fall, head injury and hospitalization.  As a health care provider, I and many others will no longer recommend flu shots to our patients.
Warm, flushed, diaphoretic. Denies difficulty swallowing/breathing. Voice low, resp. shallow, no sensitivity to light reported. BP: 136/91, HR=45, pulse palpable.
Patient presented to the ER 2 days following his first set of immunizations. He had an acute urticaria. He was treated with PRELONE for 5 days.
This is a spontaneous report from a contactable consumer (patient reported for himself). A 43-year-old male patient received the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, solution for injection, batch/lot# unknown), at the age of 43, in left arm, via an unspecified route of administration, on Apr 21, 2021, at 13:00, single dose, for COVID-19 immunization. The patient's medical history and concomitant not reported. The patient has no known allergies. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient has not tested for COVID-19. On Apr 23, 2021, patient experienced allergy/rash (itches around stomach and waste line area). The patient did not receive any treatment for the events reported. The outcome of the events: not recovered. This follow-up is being submitted to notify that the batch/lot number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information expected.
Red area about size of a half dollar and now spread to greater part of upper arm. Some itching, used hydrocortisone and ice packs.
Chest Pain      "i think i test positive for covid too" ? Breathing Problem     HPI Patient seen and examined here for shortness of breath it's been progressing for the past couple days. Patient states she's had body aches and mild headache and low-grade cough for the past 9 days. Patient returned yesterday on the airplane home from and symptoms worsened. Patient took her home Covid 19 test which was positive. Patient was vaccinated by J&J 4 months ago. She does have some mild chest pain significant shortness of breath worse with exertion. Patient is coughing with production of phlegm. She denies abdominal pain she admits to lower extremity swelling. She was with her sister in a different state who has been coughing for the past 5 days as well.      Covid-19 Vaccine (Janssen)            04/12/2021     Review of Systems Constitutional:  Positive subjective fevers, +chills, and malaise. Eyes:  No eye pain or discharge. ENMT:  No ENT changes. No neck pain or stiffness. Cardiac:  No chest pain. Respiratory:  Positive cough or positive exertional respiratory distress. GI:  Positive nausea, some vomiting, bowel changes or abdominal pain. GU:  No dysuria, frequency or burning. MS:  No myalgia, muscle weakness, joint pain or back pain. Neuro:  No headache or weakness.  No LOC. Skin:  No skin rash.  Endocrine: No history of thyroid disease or DM.
No pain at the time of injection. The nurse who gave me the vaccine was very gentle both times. She happened to be the same nurse when I went for both doses. I had a sore arm two days after the first vaccine but that's it. So I expected the same with the second dose. But my arm started to get sore the following evening and furthermore into the night. It felt very warm to the touch and when I finally looked at my bare arm, the injection site was incredibly swollen, red, and there was a white spot where the needle had entered.  The rash looked very lumpy. My arm hurt terribly and it felt like I had been stung by something. But I did not develop any other symptoms. The following morning it was slightly less swollen. Weeks later I still have what looks like a bruise on my arm but I'm fine other than that. My mom and sisters have had the Moderna vaccine without any reaction. They are all  B+ blood type and I'm B- blood type. I don't know if that has anything to do with it. I am also the only one in my family with an autoimmune disease.
bacteria in the urine; This spontaneous case was reported by a consumer and describes the occurrence of BACTERIAL TEST POSITIVE (bacteria in the urine) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History was provided by the reporter.  Concurrent medical conditions included Blood pressure and High cholesterol.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On an unknown date, the patient experienced BACTERIAL TEST POSITIVE (bacteria in the urine).   At the time of the report, BACTERIAL TEST POSITIVE (bacteria in the urine) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Urine analysis: abnormal (abnormal) Patient's lab results found bacteria in the urine..   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Treatment information was not provided.
All of my skin is burning, the inside of my skin burns. It feels like Im on fire; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 14 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 19May2021 13:45 (Batch/Lot number: unknown) at the age of 14 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SKIN BURNING SENSATION (non-serious) with onset 19May2021 04:45, outcome "not recovered", described as "All of my skin is burning, the inside of my skin burns. It feels like Im on fire". Therapeutic measures were not taken as a result of skin burning sensation.  Additional Information: Prior vaccinations within 4 weeks was reported as none. Prior to vaccination, patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Information has been received from an 88 year old female consumer with a blood pressure condition and no pertinent medical history, who on 18-Nov-2008 was vaccinated with adose of ZOSTAVAX (Oka/Merck)". Concomitant therapy included "blood pressure medicine." About a week later (26-Nov-2008) she" started noticing a little bit of breaking out on her left arm. That progressed to her right side of her body, under arm, chest and back and it looks like "big red splotches" however there is no pain or itchiness associated with it. The patient had blood work (unspecified) which "came out okay". Follow up information was received from the patient's home care aid, who called because the patient's rash was spreading and was worse than when she saw the physician on 29-Nov-2008. At that time the physician prescribed Hydroxyzine (manufacturer unknown) for itching. As of 02-Dec-2008, the outcome of the patient was not recovered. Additional information has been requested.
I am barely unable to get out of bed due to severe chest pains; I am barely unable to get out of bed due to severe chest pains; This is a spontaneous report from a contactable consumer or other non hcp. Pfizer sponsored program.  A consumer (patient) reported that a 31-year-old patient of an unspecified gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on an unspecified date May2021 as single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 for covid-19 immunisation. On an unspecified date 2021 the patient experienced a major reaction to the second Pfizer vaccine received 8 weeks ago and after 11 visits to 8 different doctors offices, patient finally know what was going on and patient wanted to make sure that they were aware so that they could be more pro-active in helping patients who are suffering. Despite being a health nut, active 31y with no previous conditions, patient was barely unable to get out of bed due to severe chest pains on an unspecified date in 2021. The events resulted in physician office visit. The outcome of the events was unknown.  Information on the lot/batch number has been requested.
A nurse reported that a male (now 44years) received and injection of tetanus toxoid in 1979 at the age of 24 years.  He experienced tightness of his chest and shortness of breath.  The pt recovered.
Hypertension with values increasing systolic by 40 mmhg and increase in diastolic by 30 mmhg for 10 days after immunization occurred. Prior to the immunization, blood pressure was 120/80 consistently! We were so relieved after 10 days that it returned to normal. No meds for hypertension were changed during this event.
Pt reported feeling very fatiqued and feverish a short time after receiving the vaccine. He took acetaminophen with little relief and then called the pharmacy in the evening feeling the same. I advised him to continue acetaminophen, check his temperature and to contact his PCP or cardiologist.
Information has been received from a registered nurse referring to an unspecified number of unspecified patients. On unknown dates, the patients were vaccinated with doses of improperly stored ROTATEQ oral liquid (Lot#: K009900, expiry date: 04-MAY-2016, exposure on 58 F for 12.75 hours from 28-MAR-2015 to 27-APR-2015; K010222, expiry date: 12-MAY-2016, exposure on 58 F for 12.75 hours from 28-MAR-2015 to 27-APR-2015; K011948, expiry date: 07-JUN-2016, exposure on 57 F for 29.75 hours from 14-AUG-2015 to 25-AUG-2015; K016275, expiry date: 20-APR-2016, exposure on 50 F for 1.5 hours on 28-MAR-2015; K020181, expiry date: 24-JUN-2016, exposure on 57 F for 48 hours from 14-AUG-2015 to 27-SEP-2015; K024700, expiry date: 30-JUL-2016, exposure on 57 F for 77.53 hours from 14-AUG-2015 to 29-NOV-2015; L001316, expiry date: 10-NOV-2016; L008057, expiry date: 01-DEC-2016; L013192, expiry date: 19-JAN-2017). No adverse effects were reported. This is one of several cases received from the same source. Additional information has been requested.
COVID-19; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On DEC-2021, the patient experienced covid-19. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from covid-19 on DEC-2021. This report was non-serious.
Headache, muscle weakness, feeling tired, chills, weak, rash, itching, swollen, red, severe dizziness
Second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping; Second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping; Second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping; Second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping; Second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping; This is a spontaneous report from a contactable consumer (patient). A 41-years-old non-pregnant female patient received second dose of bnt162b2 (BNT162B2, solution for injection, Lot Number: EW0175), via an unspecified route of administration, administered in Arm Right on 01May2021 16:00 (at the age of 41-year-old) as Dose 2, Single for covid-19 immunization. The patient received first dose of BNT162B2 (Lot number:ER8731) via an unspecified route of administration, administered in Arm Right on 01May10Apr2021 16:00 (at the age of 41-year-old) as Dose 1, Single for covid-19 immunization. Medical history was none (no). Patient had no known allergies. The patient did not receive any other vaccine within 4 weeks. The patient neither diagnosed with COVID-19 prior to vaccination nor been tested for COVID-19 after the vaccination. The patient's concomitant medications were not reported. On 11Apr2021, the patient experienced second shot: 102.6 fever, swollen lymph node, fatigue, aches, GI cramping. The patient did not receive any treatment for the events. The patient underwent lab tests and procedures which included body temperature of 100.6 and body temperature of 102.6. On an unknown date, the patient had recovered from all the events.   No follow-up attempts were needed. No further information was expected.
Shortness of Breath, Palpitations, Decreased Ejection Fraction of 45 %, Severe biventricular dilation, Hikar lymphadenopathy
GENERALIZED REDNESS, SWELLING AND HOT TO TOUCH RIGHT DELTOID EXTENDING DOWN TO RIGHT ELBOW
the second dose of VARIVAX intramuscularly; black bruise that spread from the injection site within a day or so; black bruise that spread from the injection site within a day or so; This spontaneous report was received from a pharmacist and refers to a 25-year-old female patient. The patient's concurrent conditions, medical history and concomitant medications were not reported.  On 09-OCT-2019, the patient was vaccinated with the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneously lot # R017636, expiration date 20-JUN-2020 (anatomical location not reported), for prophylaxis needed for internship. On unspecified date in October 2019, within a day or so after being vaccinated, the patient developed a black bruise that spread from the injection site within a day or so. The patient did not seek a medical attention and the bruise lasted about a week or two, and the patient recovered on unspecified date in October 2019. On an unknown date in 2019, the patient was vaccinated with the second dose of varicella virus vaccine live (oka/merck) (VARIVAX) intramuscularly lot # R017636, expiration date 20-JUN-2020 (anatomical location not reported), for prophylaxis needed for internship. There were no adverse symptoms after the second dose of varicella virus vaccine live (oka/merck) (VARIVAX).  The causality assessment was not provided.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 12-NOV-2015 (also reported as today), the patient was vaccinated with a dose of ZOSTAVAX vial (lot # L025001, expiration date 06-OCT-2016, subcutaneously, dose and route of administration were not reported) that was reconstituted with distilled water which was outside the labeled recommendations in the ZOSTAVAX prescribing information. No adverse effect was reported. Additional information has been requested.
Per MCIR patient received two doses of Moderna COVID-19 vaccines on 5/1/2021 and 5/29/2021 at outside facility; subsequently admitted to our hospital and diagnosed with COVID on 9/9/2021
redness at injection site; soreness at injection site; muscle pain; tiredness; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2019, the patient received the 1st dose of Shingrix (intramuscular). On an unknown date, less than 2 months after receiving Shingrix, the patient experienced injection site erythema, injection site pain, muscle pain and tiredness. On an unknown date, the outcome of the injection site erythema, injection site pain, muscle pain and tiredness were recovered/resolved.   It was unknown if the reporter considered the injection site erythema, injection site pain, muscle pain and tiredness to be related to Shingrix.  Additional details were provided as follows: The patient reported the case for himself. The patient received Shingrix about 2 months before the reporting date. The patient experienced redness at injection site, soreness at injection site, muscle pain, tiredness. All of these events were resolved in about one week. The patient consented to follow up and provided his doctor's details.
6/1/00, pt experienced a fever with a dx of URI. On 6/4/00, the fever remained but otitis media had developed and was prescribed Lorabid. On 6/7/00, the fever continued, but the pt developed pneumonia and was prescribed Rocephin. On 6/8/00 the fever was still present and the pt was hospitalized. Also diagnosed with febrile seizure.
Systemic: Fainting / Unresponsive-Severe, Systemic: Hypotension-Medium, Additional Details: the next day patient said he was okay.
Crying less more than 12 hours. Hypertonic, not sleeping, low intake, fever > 101 for 3 days, inconsolable.  No site reaction. Prescribed: Ibuprofen, Tylenol.
Within an hour experienced swelling and discomfort at injection site. Within 4 hours left arm became extremely swollen and painful to move or touch. Within 12 hours left arm markedly swollen from shoulder to elbow, measuring 1.5 inches larger than right arm. In addition developed sore throat, cough and sinus congestion. Swelling resolving after 72 hours.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.   Some of patient received booster dose on 1-Nov-2021, 05-Nov-2021, 11-Nov-2021 and 12-Nov-2021. No vial went any temperature excursions.   Most recent FOLLOW-UP information incorporated above includes: On 19-Nov-2021: In additional information included suspect administration date were updated. On 19-Nov-2021: Follow-up information included about patients details. On 19-Nov-2021: Significant FU appended (Second reporter Information is updated).
The patient presented to the pharmacy on 10-4-11 and underneath where the PNEUMOVAX was administered arm was red and swollen.
Localized reaction at site of injection rash, hives, wheal (or welt) appeared.
rash in the stomach; Chills; terrific pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (terrific pain), RASH (rash in the stomach) and CHILLS (Chills) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history). Concomitant products included ISOSORBIDE and PANTOPRAZOLE for an unknown indication.   On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced PAIN (terrific pain) and CHILLS (Chills). On 18-Jan-2021, the patient experienced RASH (rash in the stomach). At the time of the report, PAIN (terrific pain) and CHILLS (Chills) had resolved and RASH (rash in the stomach) had not resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: NNI
Initial information received on 08 November 2013 from a healthcare professional (pharmacist). A 75 year old female patient received FLUZONE HD (lot number, dose, route and site not reported) on 02 November 2013 (to be confirmed). On 04 November 2013, 48 hours later, the patient was admitted to hospital with anaphylaxis symptoms of facial swelling, throat swelling and difficulty breathing. The reporter had no further details about the vaccination as the patient was vaccinated at a different facility. At the time of this report the patient was still hospitalized, but was expecting to be discharged. The patient concomitant medications at the time of vaccination were reported as an ACE inhibitor and Lisinopril, dose not reported. Treatment details or laboratory results were not reported. Further details were not available at the time of this report. The patient outcome was unknown. Documents held by sender: None.
pt recv vax 5DEC97 & 7DEC97 pt returned w/ c/o swollen & painful arm @ inj site;inj site shown as 4cm indurated area w/erythema;
The patient received a dose of the Pfizer COVID vaccine last Monday (4/3/2023) in employee health.  She called employee health back and reported that she had a whole-body rash after the COVID booster vaccine.  No other symptoms besides body rash